Navigation Links
Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion

JUPITER, Fla., April 10, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today that its President and CEO, Mark Emalfarb , will speak at the Advanced Biofuels Leadership Conference in Washington, DC, during its conference session: Hot Technologies & Products, at 2:30 p.m. EDT on April 17, 2013.


The Advanced Biofuels Leadership Conference has become one of the largest gatherings of CEOs, senior executives, strategic partners, financiers, equity analysts, policymakers and industry suppliers in the Advanced Biofuels & Renewable Chemicals and Biomaterials industries in North America. The conference brings these leaders together to showcase leading companies, technologies and business strategies, and to discuss crucial technologies, partnership, financial strategies, and energy, agricultural, tax and trade policy issues, that together are charting the future of the Biofuels & Renewable Chemicals and Biomaterials industries in the US and Internationally.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries. Please visit Dyadic's website at

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International To Present At World Biofuels Markets
2. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
3. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
4. 12th U.S. Patent Issued To Dyadic International
5. Dyadic International Reports 2012 Third Quarter Financial Results
6. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
7. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
8. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
9. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
10. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
11. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... SonaCare Medical, LLC, a ... it received de novo clearance from the U.S. Food and Drug Administration (FDA) ... prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to ...
(Date:10/12/2015)... and BRUSSELS , Oct. 12, 2015 /PRNewswire/ ... today presented additional findings from an exploratory sub-study of the ... were presented today in an oral plenary session at the ... Meeting in Seattle . 2 ... The small exploratory sub-study data showed that, at month ...
(Date:10/12/2015)... Oct. 12, 2015  Rebiotix Inc. today announced ... designated its lead Microbiota Restoration Therapy (MRT) RBX2660 ... recurrent Clostridium difficile (C diff) infection, ... causes 29,000 deaths in the U.S. annually. 1 ... that was founded to revolutionize the treatment of ...
(Date:10/12/2015)... 2015  Patara Pharma, a clinical-stage biotechnology company ... and conditions, today announced the closing of a ... with the close of its sale of preferred ... Security Agreement with Silicon Valley Bank whereby the ... will use the funds from the financing to ...
Breaking Biology Technology:
(Date:10/6/2015)... , Oct. 6, 2015 Track Group, Inc. ... that it has signed a contract with the Virginia ... the full range of sentences under the Department,s oversight. ... the Americas. "This contract with the Virginia DOC will ... US and advances our position as a trusted leader ...
(Date:10/5/2015)... October 5, 2015 ... for NXT-ID, Inc. (NASDAQ: NXTD ), a biometric ... --> ) releases the ... NXTD ), a biometric authentication company focused on ... Technology Group ( ) releases the ...
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
Breaking Biology News(10 mins):